1. Patients launch $1.27 million crowdfunding campaign for ME/CFS gut microbiome study.
    Check out the website, Facebook and Twitter. Join in donate and spread the word!
9th Invest in ME International ME Conference, 2014 - Part 1: Autoimmunity and ME
Mark Berry begins a series of articles on the 9th Invest in ME International ME Conference in London, with a look at three presentations on autoimmunity
Discuss the article on the Forums.

Adaptive Bio receives US patent for next generation immunosequencing field

Discussion in 'Other Health News and Research' started by Ema, Dec 12, 2013.

  1. Ema

    Ema Senior Member

    Messages:
    3,337
    Likes:
    3,618
    Midwest USA
    Adaptive Biotechnologies Corporation, a pioneer in the field of genomic immune profiling, has obtained a notice of allowance in US Patent Application Serial No. 12/794,507, titled “Method of Measuring Adaptive Immunity,” exclusively licensed by Adaptive Biotechnologies from the Fred Hutchinson Cancer Research Centre.

    The complexity of the adaptive immune system, marked by millions of unique genetic receptors on the surface of immune fighter cells (T-cells and B-cells), is what enables the body to defend against a vast array of potential pathogens. A critical first step in profiling the adaptive immune system is the generation of millions of replicas of the DNA of these receptors to prepare them for high-throughput sequencing. Strands of nucleic acid called primers are required for successful DNA replication, or amplification. In order to account for all of the possible receptors of the immune system, the Company first pioneered immune profiling by combining these primers together into one reaction, referred to as a multiplex polymerase chain reaction (PCR).
    The allowed claims for this foundational case broadly cover compositions and methods for Adaptive’s revolutionary immunoSEQ assay technology, which use these multiplex PCR primers in a single reaction to provide high-resolution analysis of a subject’s adaptive immune system. This powerful, enabling technology is increasingly being used for diverse clinical applications to monitor a wide variety of immune-mediated diseases, including cancer, autoimmune disorders, transplant response and infectious diseases. This broad patent positions Adaptive as a significant intellectual property stakeholder for next generation adaptive immune system analysis technologies.
    “We are thrilled to have received this allowance from the USPTO,” remarked CEO and co-founder, Chad Robins. “Adaptive is a pioneer in the immunosequencing field and we are amassing an intellectual property portfolio that builds off of this foundational case to support our pipeline of assays that offer researchers and clinicians a reliable, quantitative method to characterize the adaptive immune system.” Robins further explained that the company has already launched its clonoSEQ assay for monitoring Minimal Residual Disease (MRD) in blood-based cancers and anticipates the launch of other assay into the clinic in the near future to support the diagnosis and staging of cancer patients.

    http://www.pharmabiz.com/NewsDetails.aspx?aid=78254&sid=2
    heapsreal likes this.
  2. heapsreal

    heapsreal iherb 10% discount code OPA989,

    Messages:
    7,246
    Likes:
    4,570
    australia (brisbane)
    How do we get it?
  3. Valentijn

    Valentijn Activity Level: 3

    Messages:
    6,335
    Likes:
    9,095
    Amersfoort, Netherlands
    Having a US patent means pretty much nothing. Anyone can get one for damned near anything, even if it's for something that doesn't exist and probably never will exist.
    Snowdrop likes this.

See more popular forum discussions.

Share This Page